Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 241 AL 255

Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review

Kaufman KR, Newman NB, Dawood A.

Ann Clin Psychiatry. 2014 Aug;26(3):187-91.

A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analyses of intervention effect of ginkgo

Yang M, Xu DD, Zhang Y, Liu X, Hoeven R, Cho WC.

Am J Chin Med. 2014;42(3):505-21. doi: 10.1142/S0192415X14500335.

An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease

Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR.

Curr Alzheimer Res. 2014;11(6):564-73. doi: 10.2174/1567205011666140616113406.

Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial

Aguiar P, Monteiro L, Feres A, Gomes I, Melo A.

Curr Alzheimer Res. 2014;11(6):532-7. doi: 10.2174/1567205011666140618102224.

[Vitamin D and Alzheimer's disease: from an intriguing idea to a therapeutic option]

Annweiler C.

Biol Aujourdhui. 2014;208(1):89-95. doi: 10.1051/jbio/2014005. Epub 2014 Jun 23.

Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials

Rijpma A, Meulenbroek O, Olde Rikkert MG.

Ageing Res Rev. 2014 Jul;16:105-12. doi: 10.1016/j.arr.2014.06.002. Epub 2014 Jun 27.

Nanotechnology and Alzheimer's disease: what has been done and what to do

Ruozi B, Belletti D, Pederzoli F, Veratti P, Forni F, Vandelli MA, Tosi G.

Curr Med Chem. 2014;21(36):4169-85. doi: 10.2174/0929867321666140716100056.

Is cognitive training an effective treatment for preclinical and early Alzheimer's disease?

Gates NJ, Sachdev P.

J Alzheimers Dis. 2014;42 Suppl 4:S551-9. doi: 10.3233/JAD-141302.

Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease

Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, Sujaku T, Yokokawa S, Hoshii N, Noguchi H, Bille A.

Psychogeriatrics. 2014 Sep;14(3):165-74. doi: 10.1111/psyg.12055. Epub 2014 Sep 3.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease

Wattmo C, Londos E, Minthon L.

BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.

Amyloid imaging in Alzheimer's disease: a literature review

Saidlitz P, Voisin T, Vellas B, Payoux P, Gabelle A, Formaglio M, Delrieu J.

J Nutr Health Aging. 2014 Jul;18(7):723-40. doi: 10.1007/s12603-014-0507-3.

Tau PET imaging in Alzheimer's disease

Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6.

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

Wilkinson D, Windfeld K, Colding-Jørgensen E.

Lancet Neurol. 2014 Nov;13(11):1092-1099. doi: 10.1016/S1474-4422(14)70198-X. Epub 2014 Oct 5.

Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product

Sadhu A, Upadhyay P, Agrawal A, Ilango K, Karmakar D, Singh GP, Dubey GP.

Clin Drug Investig. 2014 Dec;34(12):857-69. doi: 10.1007/s40261-014-0235-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias